Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

VOLUNTARY ANNOUNCEMENT QINGHAI PHARMACEUTICAL'S HYDROMORPHONE HYDROCHLORIDE INJECTION GRANTED DRUG REGISTRATION CERTIFICATE BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by the board of directors (the "**Board**") of Kaisa Health Group Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep holders of the Company's securities and potential investors of the Company updated on the Group's latest business developments.

The Board is pleased to announce that Hydromorphone Hydrochloride Injection (specification: 1ml: 2mg), a product of Qinghai Pharmaceutical Co., Ltd. ("**Qinghai Pharmaceutical**"), a subsidiary of the Company, successfully obtained the "Drug Registration Certificate" issued by the National Medical Products Administration of China ("**NMPA**") on 21 July 2026, and has been approved for domestic production registration.

Hydromorphone Hydrochloride Injection is used for moderate-to-severe cancer pain, acute postoperative pain, and intensive care analgesia, showing a sustained and stable inelastic clinical demand. As a narcotic drug, it is subject to extremely high entry barriers regarding research and development, review and approval, and production. It has been included in the "Catalogue of Narcotic Drugs for Medical Use (2025 Edition)" (jointly issued by the NMPA, the Ministry of Public Security, and the National Health Commission). It serves as a standard potent analgesic in domestic clinical treatment for moderate-to-severe cancer pain and severe acute postoperative pain, making it an essential therapeutic drug for hospitals at Grade II and above.

According to PRC regulations (《國家藥監局關於發佈麻醉藥品和精神藥品實驗研究管理規定的公告(2025年第51號》，附件2《麻醉藥品和精神藥品生產企業數量規定》), the maximum number of designated manufacturers for narcotic drugs such as Hydromorphone Hydrochloride Injection is three, representing a highly concentrated industry competitive landscape. Upon successfully obtaining the registration, Qinghai Pharmaceutical has become one of the three companies across China which holds valid production registration certificate for this product.

The approval of this product substantially enriches the Group's high-barrier narcotic drug pipeline, consolidates Qinghai Pharmaceutical's scarce competitive advantage in the domestic narcotic analgesic sector, and is expected to bring sustained revenue growth to the Group's businesses in the long run.

By Order of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman and Executive Director

Hong Kong, 27 July 2026

As at the date of this announcement, the Board comprises Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Ms. Luo Tingting, Mr. Xie Binhong, Mr. Yang Feng and Mr. Ye Haoda as executive directors; and Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying as independent non-executive directors.